Median Tumor Development Time Supplementary Figure 1 a b A20 Lymphoma Lenalidomide: 5 or 50 mg/kg i.p. for 35 consecutive days DNA vaccination (50 ug/mouse) Day 1 14 28 35 42 a continuous schedule for 35 consecutive days A20 Lymphoma Lenalidomide: 5 or 50 mg/kg i.p. DNA vaccination (50 ug/mouse) Day 4 14 28 35 42 7 18 21 32 an intermittent schedule c Group# Treatment No. of mice Median Tumor Development Time 1 50 mg pMCP3-sFv + Lenalidomide 5mg/kg for 35 consecutive days 10 33 2 50 mg pMCP3-sFv + Lenalidomide 50mg/kg for 35 consecutive days 25 3 50 mg pMCP3-sFv + Lenalidomide 5mg/kg intermittently (Days 4,7,18,21,32, 35) 30 4 50 mg pMCP3-sFv + Lenalidomide 50mg/kg intermittently (Days 4,7,18,21,32,35) 5 50 mg pMCP3-sFv alone 26.5 6 PBS 23.5

Supplementary Figure 2

Supplementary Figure 3 Naïve mice A20-challenged mice No treatment   Naïve mice A20-challenged mice No treatment Lenalidomide Cyclophosphamide MDSC Mean 1.57 11.47 1.39 8.26 SE 0.34 1.07 0.05 1.35 Treg 18.15 31.05 17.59 20.39 0.58 1.49 0.62 1.13 NK 8.53 6.60 8.54 4.21 0.40 0.51 0.29